Jae Yong Choi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8091718/publications.pdf

Version: 2024-02-01

331670 265206 1,942 71 21 42 h-index citations g-index papers 73 73 73 2597 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Developmental complex trauma induces the dysfunction of the amygdala-mPFC circuit in the serotonergic and dopaminergic systems. Biochemical and Biophysical Research Communications, 2022, 605, 104-110.	2.1	1
2	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
3	Validation of Image Qualities of a Novel Four-Mice Bed PET System as an Oncological and Neurological Analysis Tool. Journal of Imaging, 2021, 7, 43.	3.0	3
4	Combined Model of Aggregation and Network Diffusion Recapitulates Alzheimer's Regional Tau-Positron Emission Tomography. Brain Connectivity, 2021, 11, 624-638.	1.7	8
5	Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer's Disease Mouse Model. International Journal of Molecular Sciences, 2021, 22, 9374.	4.1	7
6	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
7	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.8	73
8	The Impact of Amyloid- \hat{l}^2 or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease. Journal of Alzheimer's Disease, 2020, 78, 573-585.	2.6	10
9	Inhibition of Colony-Stimulating Factor 1 Receptor by PLX3397 Prevents Amyloid Beta Pathology and Rescues Dopaminergic Signaling in Aging 5xFAD Mice. International Journal of Molecular Sciences, 2020, 21, 5553.	4.1	30
10	Evaluation of the neuroprotective effect of taurine in Alzheimer's disease using functional molecular imaging. Scientific Reports, 2020, 10, 15551.	3.3	23
11	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	9.0	80
12	Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson's Animal Model. Molecular Imaging and Biology, 2020, 22, 1031-1042.	2.6	26
13	Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2879-2886.	6.4	24
14	Effect of Short-Term LTE RF-EMF Exposure on Dopamine Signaling and Behaviors in Mice. The Journal of Korean Institute of Electromagnetic Engineering and Science, 2020, 31, 847-850.	0.3	0
15	Age dependency of mGluR5 availability in 5xFAD mice measured by PET. Neurobiology of Aging, 2019, 84, 208-216.	3.1	27
16	Effects of Pâ€gp and Bcrp as brain efflux transporters on the uptake of [¹⁸ F]FPEB in the murine brain. Synapse, 2019, 73, e22123.	1.2	1
17	Preparing a ⁶⁸ Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis. Journal of Visualized Experiments, 2019, , .	0.3	3
18	Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study. Journal of Nuclear Medicine, 2019, 60, 1611-1621.	5.0	75

#	Article	IF	CITATIONS
19	ICâ€Pâ€164: MEDIAL TEMPORAL TAU CAN BE A PREDICTOR OF AMYLOIDâ€POSITIVITY IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2019, 15, P130.	0.8	0
20	ICâ€Pâ€163: TEMPORAL TRAJECTORIES OF IN VIVO TAU AND AMYLOIDâ€Î² ACCUMULATION IN ALZHEIMER'S DIS Alzheimer's and Dementia, 2019, 15, P130.	FASE.	0
21	18F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia. Neurobiology of Aging, 2019, 75, 187-197.	3.1	12
22	Predicted sequence of cortical tau and amyloid- \hat{l}^2 deposition in Alzheimer disease spectrum. Neurobiology of Aging, 2018, 68, 76-84.	3.1	39
23	${\sf A}\hat{\sf I}^2$ pathology downregulates brain mGluR5 density in a mouse model of Alzheimer. Neuropharmacology, 2018, 133, 512-517.	4.1	25
24	Predominant subcortical accumulation of 18 F-flortaucipir binding in behavioral variant frontotemporal dementia. Neurobiology of Aging, 2018, 66, 112-121.	3.1	15
25	Distinct patterns of amyloidâ€dependent tau accumulation in Lewy body diseases. Movement Disorders, 2018, 33, 262-272.	3.9	54
26	Effects of hypothyroidism on serotonin 1A receptors in the rat brain. Psychopharmacology, 2018, 235, 729-736.	3.1	6
27	Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 432-442.	6.4	51
28	Off-Target ¹⁸ F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation. Journal of Nuclear Medicine, 2018, 59, 117-120.	5.0	70
29	P1â€382: COMPARISON OF AD PATHOLOGIES IN HYPERTENSIVE SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT AND CEREBRAL AMYLOID ANGIOPATHY. Alzheimer's and Dementia, 2018, 14, P445.	0.8	0
30	ICâ€Pâ€078: CLINICAL SIGNIFICANCE OF A/T/N SYSTEM IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT PATIENTS. Alzheimer's and Dementia, 2018, 14, P69.	0.8	0
31	P1â€383: ¹⁸ Fâ€FLORTAUCIPIR BINDING PATTERNS IN CLINICAL SUBTYPES OF PRIMARY PROGRESSIN APHASIA. Alzheimer's and Dementia, 2018, 14, P446.	VE 0.8	0
32	Early Detection of A <i>\hat{l}^2</i> Deposition in the 5xFAD Mouse by Amyloid PET. Contrast Media and Molecular Imaging, 2018, 2018, 1-7.	0.8	23
33	Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms. Journal of Movement Disorders, 2018, 11, 1-12.	1.3	9
34	Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer's disease. Neurobiology of Aging, 2017, 53, 103-111.	3.1	66
35	18F-AV-1451 PET Imaging in Three Patients with Probable Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2017, 57, 711-716.	2.6	18
36	¹⁸ Fâ€AVâ€1451 binds to putamen in multiple system atrophy. Movement Disorders, 2017, 32, 171-173.	3.9	26

#	Article	IF	CITATIONS
37	Preliminary PET Study of ¹⁸ F-FC119S in Normal and Alzheimer's Disease Models. Molecular Pharmaceutics, 2017, 14, 3114-3120.	4.6	10
38	¹⁸ F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome. Neurology, 2017, 89, 1170-1178.	1.1	56
39	Synthesis and Preliminary Evaluation of ⁶⁸ Gaâ€NOTAâ€Biphenyl (RGDyK) for the Quantification of Integrin α _v β ₃ . Bulletin of the Korean Chemical Society, 2017, 38, 1415-1418.	1.9	O
40	[S2â€"01â€"04]: IN VIVO CORTICAL SPREADING OF TAU AND AMYLOID. Alzheimer's and Dementia, 2017, 13, P5	4d. 8	0
41	Subcortical ¹⁸ Fâ€AVâ€1451 binding patterns in progressive supranuclear palsy. Movement Disorders, 2017, 32, 134-140.	3.9	109
42	[P1–224]: ¹⁸ Fâ€AV1451 PET IMAGING IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P329.	0.8	0
43	[P2–346]: EXCESSIVE NEOCORTICAL TAU ACCUMULATION IN DOWN SYNDROME. Alzheimer's and Dementia, 2017, 13, P754.	0.8	O
44	[ICâ€Pâ€179]: PRINCIPAL COMPONENT ANALYSIS OF TAU PET IN ALZHEIMER'S DISEASE AND HEALTHY ELDERLY. Alzheimer's and Dementia, 2017, 13, P133.	0.8	0
45	[P1–365]: PREDOMINANT SUBCORTICAL ¹⁸ Fâ€AVâ€1451 BINDING IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P399.	0.8	O
46	[P1â€"386]: DISTINCT TAU ACCUMULATION PATTERN IN DEMENTIA WITH LEWY BODY. Alzheimer's and Dementia, 2017, 13, P414.	0.8	1
47	[P2–342]: ¹⁸ Fâ€AVâ€1451 BINDS TO THE MOTORâ€RELATED SUBCORTICAL GRAY AND WHITE M CORTICOBASAL SYNDROME. Alzheimer's and Dementia, 2017, 13, P753.	MATTER IN	O
48	In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Annals of Neurology, 2016, 80, 247-258.	5.3	375
49	P2â€232: TAU Burden and Cognition in Earlyâ€Onset Versus Lateâ€Onset Alzheimer's Disease Spectrum. Alzheimer's and Dementia, 2016, 12, P711.	0.8	1
50	P3-263: TAU PET in Alzheimer'S Disease and Mild Cognitive Impairment. , 2016, 12, P933-P933.		0
51	O4-07-04: In Vivo Cortical Spreading Pattern of TAU and Amyloid Pathology in the Alzheimer's Disease Spectrum., 2016, 12, P349-P349.		1
52	Environmental enrichment enhances synaptic plasticity by internalization of striatal dopamine transporters. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 2122-2133.	4.3	31
53	Human Radiation Dosimetry of [18F]AV-1451(T807) to Detect Tau Pathology. Molecular Imaging and Biology, 2016, 18, 479-482.	2.6	13
54	Tau PET in Alzheimer disease and mild cognitive impairment. Neurology, 2016, 87, 375-383.	1.1	208

#	Article	IF	Citations
55	Tau Accumulation in Primary Motor Cortex of Variant Alzheimer's Disease with Spastic Paraparesis. Journal of Alzheimer's Disease, 2016, 51, 671-675.	2.6	13
56	Time and cost effective production of sodium [18F]fluoride using a dedicated automation module with disposable cassettes for GMP environment. Journal of Radioanalytical and Nuclear Chemistry, 2016, 309, 983-987.	1.5	2
57	Biodistribution and Radiation Dosimetry of [18F]Mefway in Humans. Molecular Imaging and Biology, 2016, 18, 803-806.	2.6	3
58	Optimal timing of [18 F]Mefway PET for imaging the serotonin 1A receptor in healthy male subjects. Applied Radiation and Isotopes, 2016, 107, 127-132.	1.5	3
59	P-Glycoprotein, not BCRP, Limits the Brain Uptake of [18F]Mefway in Rodent Brain. Molecular Imaging and Biology, 2016, 18, 267-273.	2.6	5
60	Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system. Synapse, 2015, 69, 453-460.	1.2	24
61	[18F]FPEB and [18F]FDEGPECO comparative study of mGlu5 quantification in rodent brain. Applied Radiation and Isotopes, 2015, 98, 103-107.	1.5	4
62	18F-Mefway PET Imaging of Serotonin 1A Receptors in Humans: A Comparison with 18F-FCWAY. PLoS ONE, 2015, 10, e0121342.	2.5	14
63	Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image. PLoS ONE, 2015, 10, e0132585.	2.5	25
64	A Computed Tomography-Based Spatial Normalization for the Analysis of [$<$ sup $>$ 18 $<$ /sup $>$ F] Fluorodeoxyglucose Positron Emission Tomography of the Brain. Korean Journal of Radiology, 2014, 15, 862.	3.4	7
65	Acute physical stress induces the alteration of the serotonin 1A receptor density in the hippocampus. Synapse, 2014, 68, 363-368.	1.2	12
66	Determination of optimal acquisition time of [18F]FCWAY PET for imaging serotonin 1A receptors in the healthy male subjects. Applied Radiation and Isotopes, 2014, 89, 141-145.	1.5	4
67	Translational possibility of [¹⁸ F]Mefway to image serotonin 1A receptors in humans: Comparison with [¹⁸ F]FCWAY in rodents. Synapse, 2014, 68, 595-603.	1.2	3
68	Dopaminergic neuron destruction reduces hippocampal serotonin 1A receptor uptake of trans -[18 F]Mefway. Applied Radiation and Isotopes, 2014, 94, 30-34.	1.5	4
69	Optimization of the radiosynthesis of [¹⁸ F]MEFWAY for imaging brain serotonin 1A receptors by using the GE TracerLab FX _{FNâ€Pro} module. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 589-594.	1.0	8
70	Effective MicroPET imaging of brain 5â€HT _{1A} receptors in rats with [¹⁸ F]MeFWAY by suppression of radioligand defluorination. Synapse, 2012, 66, 1015-1023.	1.2	13
71	Evaluation of dopamine transporters and D2 receptors in hemiparkinsonian rat brains in vivo using consecutive PET scans of [18F]FPCIT and [18F]fallypride. Applied Radiation and Isotopes, 2012, 70, 2689-2694.	1.5	13